1. Home
  2. SNGX vs SLXN Comparison

SNGX vs SLXN Comparison

Compare SNGX & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • SLXN
  • Stock Information
  • Founded
  • SNGX 1987
  • SLXN 2008
  • Country
  • SNGX United States
  • SLXN Israel
  • Employees
  • SNGX N/A
  • SLXN N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • SLXN
  • Sector
  • SNGX Health Care
  • SLXN
  • Exchange
  • SNGX Nasdaq
  • SLXN NYSE
  • Market Cap
  • SNGX 7.4M
  • SLXN 5.0M
  • IPO Year
  • SNGX 1987
  • SLXN N/A
  • Fundamental
  • Price
  • SNGX $2.39
  • SLXN $1.08
  • Analyst Decision
  • SNGX
  • SLXN Strong Buy
  • Analyst Count
  • SNGX 0
  • SLXN 1
  • Target Price
  • SNGX N/A
  • SLXN $9.00
  • AVG Volume (30 Days)
  • SNGX 51.7K
  • SLXN 31.5M
  • Earning Date
  • SNGX 03-14-2025
  • SLXN 02-25-2025
  • Dividend Yield
  • SNGX N/A
  • SLXN N/A
  • EPS Growth
  • SNGX N/A
  • SLXN N/A
  • EPS
  • SNGX N/A
  • SLXN N/A
  • Revenue
  • SNGX $364,183.00
  • SLXN N/A
  • Revenue This Year
  • SNGX N/A
  • SLXN N/A
  • Revenue Next Year
  • SNGX $76.64
  • SLXN N/A
  • P/E Ratio
  • SNGX N/A
  • SLXN N/A
  • Revenue Growth
  • SNGX N/A
  • SLXN N/A
  • 52 Week Low
  • SNGX $1.83
  • SLXN $0.21
  • 52 Week High
  • SNGX $14.88
  • SLXN $13.56
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 43.83
  • SLXN N/A
  • Support Level
  • SNGX $2.25
  • SLXN N/A
  • Resistance Level
  • SNGX $2.60
  • SLXN N/A
  • Average True Range (ATR)
  • SNGX 0.15
  • SLXN 0.00
  • MACD
  • SNGX 0.03
  • SLXN 0.00
  • Stochastic Oscillator
  • SNGX 52.27
  • SLXN 0.00

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.

Share on Social Networks: